How to use endocrine therapy in premenopausal women with ER+ metastatic breast cancer

In this educational video of the 'How To' series, Fatima Cardoso explains how to treat premenopausal women with ER-positive, HER2-negative metastatic breast cancer.

They are typically excluded from the clinical trials and the question of adequate ovarian suppression and inducing menopause is central to enable the possibility for these patients to receive endocrine therapy or any treatment option evaluated in the postmenopausal setting.

View and download the ESMO Guidelines Slide Set on Advanced breast cancer - algorithms from the 4th ESO-ESMO International Consensus Guidelines (ABC4)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings